Associate Professor, Department of Pediatrics, Dayanand Medical College and Hospital, Ludhiana, India.
Intern, Dayanand Medical College and Hospital, Ludhiana, India.
Acta Haematol. 2023;146(5):391-396. doi: 10.1159/000531448. Epub 2023 Jun 16.
Vaccination against SARS-CoV-2 is the most important weapon in the arsenal in the battle against COVID-19. There is concern about an increased risk of adverse effects in patients with transfusion-dependent thalassemia (TDT), which affects vaccine acceptance. A predesigned questionnaire was used to evaluate adverse effects (local/systemic within 90 days after vaccination) in participants >18 years of age with TDT. A total of 100 patients received 129 vaccine doses. The mean age of the patients was 24.3 ± 5.7 years, and M:F ratio of 1.6:1. Covishield (Serum Institute of India) was administered to 89% of the participants, and Covaxin (Bharat Biotech Limited) to 11% of the participants. Adverse effects were documented in 62% of the respondents and were more pronounced after the first dose (52%) compared to the second dose (9%). The most frequent adverse effects were pain at the injection site (43%) and fever (37%). All adverse effects were mild and none of the participants required hospitalization. There were no differences in adverse effects among different vaccines, in the presence or absence of comorbidities, blood groups, or ferritin levels. The SARS-CoV-2 vaccine appears to be safe for patients with TDT.
接种 SARS-CoV-2 疫苗是对抗 COVID-19 的最重要武器。人们担心输血依赖型地中海贫血（TDT）患者接种疫苗的不良反应风险增加，这影响了疫苗的接种率。我们使用预先设计的问卷评估了年龄>18 岁的 TDT 患者接种疫苗后 90 天内（局部/全身）的不良反应。共有 100 名患者接受了 129 剂疫苗。患者的平均年龄为 24.3±5.7 岁，男女比例为 1.6:1。89%的参与者接种了 Covishield（印度血清研究所），11%的参与者接种了 Covaxin（巴拉特生物技术有限公司）。62%的受访者记录了不良反应，第一剂（52%）比第二剂（9%）更明显。最常见的不良反应是注射部位疼痛（43%）和发热（37%）。所有不良反应均为轻度，无参与者需要住院治疗。不同疫苗、有无合并症、血型或铁蛋白水平之间的不良反应无差异。SARS-CoV-2 疫苗似乎对 TDT 患者是安全的。
